Company data sheet · DR Reddys Laboratories
DR Reddys Laboratories: profitable every year.
- Industry
- Pharmaceutical Preparations Manufacturing
- Headquarters
- India
- Ticker
- RDY (NYSE)
- Sources
- SEC filings (2001–2026), Stratrix's verified Decision Cases, market data and official economic statistics for India
- Data as of
- November 1, 2026
- Profitable every year. DR Reddys Laboratories made money in each of its last ten fiscal years, from ₹9.8 billion (fiscal 2018) to ₹56.5 billion (fiscal 2025).
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | ₹155 billion | ₹20 billion | |
| 2017 | ₹141 billion | ₹12 billion | |
| 2018 | ₹142 billion | ₹9.8 billion | |
| 2019 | ₹154 billion | ₹18.8 billion | |
| 2020 | ₹175 billion | ₹19.5 billion | |
| 2021 | ₹190 billion | ₹17.2 billion | |
| 2022 | ₹214 billion | ₹23.6 billion | |
| 2023 | ₹246 billion | ₹45.1 billion | |
| 2024 | ₹279 billion | ₹55.7 billion | |
| 2025 | ₹326 billion | ₹56.5 billion |
As reported in its annual filings, in INR. Losses in red.
The full data sheet · Data Plan
Everything behind these findings, ready for your board deck.
- Economic context: 5 measures for India, every year since 2016, from the official sources.
- Peer comparison: against 953 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.